20s Proteasome - Pipeline Review, H2 2020
20s Proteasome - Pipeline Review, H2 2020
SUMMARY
According to the recently published report '20s Proteasome - Pipeline Review, H2 2020'; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.
The report '20s Proteasome - Pipeline Review, H2 2020' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer and Tuberculosis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report '20s Proteasome - Pipeline Review, H2 2020'; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.
The report '20s Proteasome - Pipeline Review, H2 2020' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer and Tuberculosis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 20s Proteasome Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
20s Proteasome - Overview
20s Proteasome - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
20s Proteasome - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
20s Proteasome - Companies Involved in Therapeutics Development
Amgen Inc
Bristol-Myers Squibb Co
Centrax International Inc
HuniLife Biotechnology Inc
Lodo Therapeutics Corp
20s Proteasome - Drug Profiles
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-13608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuL-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marizomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTSV-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TIR-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
20s Proteasome - Dormant Products
20s Proteasome - Product Development Milestones
Featured News & Press Releases
Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis
Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens
May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020
May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer
Dec 11, 2019: Amgen reports positive data in multiple myeloma study
Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019
Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival
Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019
Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma
Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
Apr 25, 2019: Amgen agree to pay a total of nearly $24.75 million to resolve allegations that it paid kickbacks through copay assistance foundations
Mar 19, 2019: ONO submits supplemental application of Kyprolis for intravenous injection, a proteasome inhibitor, for additional dosage and administration for the treatment of relapsed or refractory multiple myeloma in Japan
Nov 01, 2018: Amgen to present new data on Carfilzomib at ASH 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
20s Proteasome - Overview
20s Proteasome - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
20s Proteasome - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
20s Proteasome - Companies Involved in Therapeutics Development
Amgen Inc
Bristol-Myers Squibb Co
Centrax International Inc
HuniLife Biotechnology Inc
Lodo Therapeutics Corp
20s Proteasome - Drug Profiles
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-13608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuL-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marizomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTSV-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TIR-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
20s Proteasome - Dormant Products
20s Proteasome - Product Development Milestones
Featured News & Press Releases
Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis
Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens
May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020
May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer
Dec 11, 2019: Amgen reports positive data in multiple myeloma study
Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019
Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival
Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019
Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma
Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
Apr 25, 2019: Amgen agree to pay a total of nearly $24.75 million to resolve allegations that it paid kickbacks through copay assistance foundations
Mar 19, 2019: ONO submits supplemental application of Kyprolis for intravenous injection, a proteasome inhibitor, for additional dosage and administration for the treatment of relapsed or refractory multiple myeloma in Japan
Nov 01, 2018: Amgen to present new data on Carfilzomib at ASH 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Centrax International Inc, H2 2020
Pipeline by HuniLife Biotechnology Inc, H2 2020
Pipeline by Lodo Therapeutics Corp, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Centrax International Inc, H2 2020
Pipeline by HuniLife Biotechnology Inc, H2 2020
Pipeline by Lodo Therapeutics Corp, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
